Published in Circulation on July 14, 2003
The metabolic syndrome. Endocr Rev (2008) 5.33
Metabolic syndrome: definitions and controversies. BMC Med (2011) 3.80
Alternative macrophage activation and metabolism. Annu Rev Pathol (2011) 3.59
Prevalence of diabetes mellitus in a Saudi community. Ann Saudi Med (2011) 2.83
Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care (2008) 2.66
Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation (2012) 2.51
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol (2007) 2.29
Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol (2006) 2.22
Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation (2010) 2.20
Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr (2006) 2.07
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome. Metabolism (2009) 1.76
Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study. Nutrition (2008) 1.69
The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract (2008) 1.69
Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol (2012) 1.68
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician (2013) 1.67
Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol (2007) 1.64
Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. J Epidemiol Community Health (2007) 1.59
Postoperative cognitive dysfunction after noncardiac surgery: effects of metabolic syndrome. J Anesth (2011) 1.56
Effects of a community-based healthy heart program on increasing healthy women's physical activity: a randomized controlled trial guided by Community-based Participatory Research (CBPR). BMC Public Health (2007) 1.53
Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol (2007) 1.52
Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis (2007) 1.50
Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes (2007) 1.49
Menopause and metabolic syndrome: A study of 498 urban women from western India. J Midlife Health (2010) 1.43
Prevalence of metabolic syndrome associated with body burden levels of dioxin and related compounds among Japan's general population. Environ Health Perspect (2008) 1.28
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr (2009) 1.25
Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol (2008) 1.25
Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag (2006) 1.23
Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care (2010) 1.20
Metabolic syndrome and diabetes, alone and in combination, as predictors of cardiovascular disease mortality among men. Diabetes Care (2009) 1.18
Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol (2013) 1.17
The metabolic syndrome: prevalence, associated factors, and impact on survival among older persons in rural Bangladesh. PLoS One (2011) 1.17
Systemic inflammation and the metabolic syndrome among middle-aged community volunteers. Metabolism (2010) 1.16
Metabolic syndrome and risk for heart failure in middle-aged men. Heart (2006) 1.13
Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig (2013) 1.13
Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc (2006) 1.13
Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol (2013) 1.12
Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis. Am J Clin Nutr (2015) 1.12
Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm (2013) 1.11
Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am (2008) 1.10
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol (2007) 1.10
Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J (2005) 1.10
Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health (2010) 1.10
Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. Cardiovasc Diabetol (2007) 1.09
Metabolic syndrome and urologic diseases. Rev Urol (2010) 1.09
Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study. Circulation (2009) 1.08
Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart (2007) 1.05
Neuroendocrine factors in the regulation of inflammation: excessive adiposity and calorie restriction. Exp Gerontol (2008) 1.05
Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab (2008) 1.04
Weight loss and low-intensity exercise for the treatment of metabolic syndrome in obese postmenopausal women. J Gerontol A Biol Sci Med Sci (2011) 1.03
The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev (2010) 1.02
Association of metabolic syndrome with exercise capacity and heart rate recovery in patients with coronary heart disease in the heart and soul study. Am J Cardiol (2005) 1.02
Inverse correlation between coffee consumption and prevalence of metabolic syndrome: baseline survey of the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study in Tokushima, Japan. J Epidemiol (2012) 1.02
Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China Health and Nutrition Survey 2009. Int J Obes (Lond) (2013) 1.02
Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther (2008) 1.01
Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats. Cardiovasc Diabetol (2013) 1.01
Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study. Am J Physiol Endocrinol Metab (2006) 1.00
Relationships between serum adiponectin with metabolic syndrome and components of metabolic syndrome in non-diabetic Koreans: ARIRANG study. Yonsei Med J (2011) 1.00
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care (2008) 0.98
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol (2005) 0.98
Risk factors for type 2 diabetes in groups stratified according to metabolic syndrome: a 10-year follow-up of the Tromsø Study. Eur J Epidemiol (2010) 0.97
Low-carbohydrate and high-fat intake among adult patients with poorly controlled type 2 diabetes mellitus. Nutrition (2006) 0.95
A new tool, a better tool? Prevalence and performance of the International Diabetes Federation and the National Cholesterol Education Program criteria for metabolic syndrome in different ethnic groups. Eur J Epidemiol (2007) 0.95
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2009) 0.94
Metabolic syndrome model definitions predicting type 2 diabetes and cardiovascular disease. Diabetes Care (2012) 0.94
Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care (2008) 0.94
Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. Cardiovasc Diabetol (2012) 0.93
Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults. Cardiovasc Diabetol (2011) 0.93
Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol (2004) 0.92
Circulating oxidized low-density lipoproteins and arterial elasticity: comparison between men with metabolic syndrome and physically active counterparts. Cardiovasc Diabetol (2010) 0.92
Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med (2016) 0.90
Impact of the metabolic syndrome on the clinical outcome of patients with acute ST-elevation myocardial infarction. J Korean Med Sci (2010) 0.90
The metabolic syndrome and mind-body therapies: a systematic review. J Nutr Metab (2011) 0.90
An association between TRP64ARG polymorphism of the B3 adrenoreceptor gene and some metabolic disturbances. Cardiovasc Diabetol (2011) 0.90
Effects of lifestyle interventions on inflammatory markers in the metabolic syndrome. Front Biosci (Schol Ed) (2011) 0.89
Studies on oxidative stress in liver diseases: important future trends in liver research. Med Mol Morphol (2006) 0.89
National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease? Int J Prev Med (2012) 0.89
LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia (2011) 0.89
Radiation-induced cardiovascular injury. Radiat Environ Biophys (2008) 0.89
Should C-reactive protein be a target of therapy? Diabetes Care (2011) 0.88
Metabolic syndrome in the rural population of wardha, central India: an exploratory factor analysis. Indian J Community Med (2013) 0.88
The correlation between waist circumference and ESC cardiovascular risk score: data from the German metabolic and cardiovascular risk project (GEMCAS). Clin Res Cardiol (2008) 0.88
Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc (2009) 0.88
Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol (2006) 0.88
Association of Hematological Parameters with Clustered Components of Metabolic Syndrome among Professional and Office Workers in Bangkok, Thailand. Diabetes Metab Syndr (2007) 0.88
Prevalence of metabolic syndrome in adult population from zahedan, southeast iran. Iran J Public Health (2012) 0.87
Long-term C-reactive protein variability and prediction of metabolic risk. Am J Med (2009) 0.87
Metabolic syndrome as a cardiovascular disease risk factor: patients evaluated in primary care. BMC Public Health (2008) 0.87
Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep (2010) 0.87
Dietary fiber is associated with circulating concentrations of C-reactive protein in breast cancer survivors: the HEAL study. Breast Cancer Res Treat (2011) 0.87
Metabolic syndrome, independent of its components, is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA. Diabetes Care (2010) 0.86
Gallbladder gallstone disease is associated with newly diagnosed coronary artery atherosclerotic disease: a cross-sectional study. PLoS One (2013) 0.85
Nerium oleander Distillate Improves Fat and Glucose Metabolism in High-Fat Diet-Fed Streptozotocin-Induced Diabetic Rats. Int J Endocrinol (2012) 0.85
Prevalence of metabolic syndrome components among the elderly using three different definitions: a cohort study in Finland. Scand J Prim Health Care (2012) 0.84
Hypertriglyceridemia influences the degree of postprandial lipemic response in patients with metabolic syndrome and coronary artery disease: from the CORDIOPREV study. PLoS One (2014) 0.84
Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ (2010) 0.84
Molecular determinants of the cardiometabolic phenotype. Endocr Metab Immune Disord Drug Targets (2010) 0.84
Correlation between Body Mass Index and Waist Circumference in Patients with Metabolic Syndrome. ISRN Endocrinol (2014) 0.84
The metabolic syndrome among patients with cardiovascular disease in Accra, Ghana. Ghana Med J (2011) 0.83
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med (2007) 7.96
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med (2010) 7.49
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care (2003) 5.27
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet (2012) 5.16
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11
Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med (2002) 5.10
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer (2011) 3.59
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care (2004) 3.51
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
From patients to partners: participant-centric initiatives in biomedical research. Nat Rev Genet (2012) 3.44
Outcomes of elective induction of labour compared with expectant management: population based study. BMJ (2012) 3.07
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med (2010) 2.94
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care (2002) 2.92
Potential impact of public access defibrillators on survival after out of hospital cardiopulmonary arrest: retrospective cohort study. BMJ (2002) 2.89
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 2.76
Cohort profile: updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. Int J Epidemiol (2011) 2.75
Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens (2010) 2.73
Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail (2013) 2.73
Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail (2012) 2.72
Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.63
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes (2009) 2.51
Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol (2003) 2.51
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation (2005) 2.46
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol (2005) 2.43
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes (2005) 2.42
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42
Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant (2010) 2.41
The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes (2006) 2.40
Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med (2013) 2.37
The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr (2011) 2.34
Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation (2004) 2.33